for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ.N

Latest Trade

145.91USD

Change

-4.02(-2.68%)

Volume

3,600,116

Today's Range

145.27

 - 

148.97

52 Week Range

126.10

 - 

154.25

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
149.93
Open
146.46
Volume
3,600,116
3M AVG Volume
129.50
Today's High
148.97
Today's Low
145.27
52 Week High
154.25
52 Week Low
126.10
Shares Out (MIL)
2,634.72
Market Cap (MIL)
395,023.80
Forward P/E
--
Dividend (Yield %)
2.53

Next Event

Johnson & Johnson at Leerink Global Healthcare Conference

Latest Developments

More

J&J To Expand Partnership With U.S. Dept. Of Health & Human Services To Accelerate The Discovery Of Potential COVID-19 Treatments

J&J Says On Feb 11, Board Voted To Submit Proposal At Annual Meeting Recommending Approval Of Amendment To Co's Restated Certificate Of Incorporation

Johnson & Johnson partners with U.S. Department Of Health & Human Services to develop coronavirus vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Contact Info

1 Johnson And Johnson Plz

+1.732.5242455

https://www.jnj.com/

Executive Leadership

Alex Gorsky

Chairman of the Board, Chief Executive Officer

Paulus A. Stoffels

Vice Chairman- Executive Committee, Chief Scientific Officer

Joaquin Boix Duato

Vice Chairman - Executive Committee

Joseph J. Wolk

Chief Financial Officer, Executive Vice President

Peter M. Fasolo

Chief Human Resource Officer, Executive Vice President

Key Stats

2.06 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

76.5K

2018

81.6K

2019

82.1K

2020(E)

85.8K
EPS (USD)

2017

7.300

2018

8.180

2019

8.680

2020(E)

9.042
Price To Earnings (TTM)
26.64
Price To Sales (TTM)
4.81
Price To Book (MRQ)
6.64
Price To Cash Flow (TTM)
17.85
Total Debt To Equity (MRQ)
46.57
LT Debt To Equity (MRQ)
44.55
Return on Investment (TTM)
12.42
Return on Equity (TTM)
9.73

Latest News

Latest News

BRIEF-J&J To Expand Partnership With U.S. Dept. Of Health & Human Services To Accelerate The Discovery Of Potential COVID-19 Treatments

* JOHNSON & JOHNSON TO EXPAND PARTNERSHIP WITH U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES TO ACCELERATE THE DISCOVERY OF POTENTIAL COVID-19 TREATMENTS

BRIEF-J&J Says On Feb 11, Board Voted To Submit Proposal At Annual Meeting Recommending Approval Of Amendment To Co's Restated Certificate Of Incorporation

* J&J - ON FEB 11, BOARD VOTED TO SUBMIT PROPOSAL AT ANNUAL MEETING RECOMMENDING APPROVAL OF AMENDMENT TO CO'S RESTATED CERTIFICATE OF INCORPORATION

J&J partners with U.S. agency to develop coronavirus vaccine

Johnson & Johnson <JNJ.N> said on Tuesday it was working with the Biomedical Advanced Research and Development Authority (BARDA) to speed up development of a coronavirus vaccine.

UPDATE 1-J&J partners with U.S. agency to develop coronavirus vaccine

Johnson & Johnson said on Tuesday it was working with the Biomedical Advanced Research and Development Authority (BARDA) to speed up development of a coronavirus vaccine.

Johnson & Johnson partners with U.S. agency to develop coronavirus vaccine

Johnson & Johnson <JNJ.N> said on Tuesday it was working with the Biomedical Advanced Research and Development Authority (BARDA) to speed up development of a coronavirus vaccine.

Jury orders Johnson & Johnson to pay $750 million in New Jersey talc case

Johnson & Johnson was ordered on Thursday by a New Jersey state jury to pay punitive damages of $750 million to four plaintiffs who allege that the company's Baby Powder caused their cancer, a ruling that will be reduced to around $185 million because of state laws, according...

J&J ordered to pay $750 mln in NJ talc case -lawyer

Johnson & Johnson was ordered on Thursday by a jury in a New Jersey court to pay punitive damages of $750 million to four plaintiffs who allege that the company's Baby Powder caused their cancer, according to a lawyer for the plaintiffs.

Bayer wins EU recommendation for prostate cancer drug

Bayer on Friday won an endorsement from the European Union's drug regulator for its prostate cancer drug darolutamide, putting it on track for approval, as it takes on rival products by Pfizer and Johnson & Johnson.

Johnson & Johnson working on vaccine for deadly coronavirus

Johnson & Johnson on Wednesday became the latest drugmaker to begin work on developing a vaccine for a new coronavirus that has already killed more than 100 people in China, as health authorities race to contain the outbreak.

Johnson & Johnson starts developing vaccine for coronavirus

Johnson & Johnson said on Wednesday it is working on developing a vaccine for the new coronavirus that has killed more than 100 people in China.

J&J CEO questioned over stock sale ahead of story on asbestos in Baby Powder

Johnson & Johnson <JNJ.N> Chief Executive Alex Gorsky on Monday faced questions from plaintiffs lawyers over the timing of his sale of company stock, as he testified for the first time in a jury trial over allegations that the company's Baby Powder causes cancer.

J&J CEO to testify at trial for first time on Baby Powder risks

Johnson & Johnson Chief Executive Officer Alex Gorsky was set to be called as a witness on Monday in what would be his first appearance in a jury trial over allegations that the company's Baby Powder causes cancer.

J&J chief testifies he did not read all documents related to asbestos in talc

Johnson & Johnson Chief Executive Alex Gorsky told a jury Monday that he did not read all the internal company documents related to potential asbestos contamination in Johnson's Baby Powder.

J&J CEO to testify at trial for first time on Baby Powder risks

Johnson & Johnson Chief Executive Officer Alex Gorsky was set to be called as a witness on Monday in what would be his first appearance in a jury trial over allegations that the company's Baby Powder causes cancer.

J&J forecasts weak annual profit, misses revenue estimates

Johnson & Johnson on Wednesday forecast 2020 profit below Wall Street estimates and said increased competition for its off-patent treatments could somewhat limit growth in the top-earning pharmaceuticals unit.

Johnson & Johnson quarterly profit jumps 32%

Johnson & Johnson on Wednesday posted a 32% rise in fourth-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.

Judge slashes $8 billion Risperdal award against Johnson & Johnson to $6.8 million

A Pennsylvania judge on Friday slashed to $6.8 million from $8 billion a punitive damages award against Johnson & Johnson to a man who said it failed to warn that boys using its antipsychotic drug Risperdal could grow breasts.

Judge slashes $8 bln Risperdal award against Johnson & Johnson to $6.8 mln

A Pennsylvania judge on Friday slashed to $6.8 million from $8 billion a punitive damages award against Johnson & Johnson for allegedly failing to warn men that they could grow breasts by using its antipsychotic drug Risperdal.

China regulator approves imports of J&J's Tremfya

China has approved imports of Johnson & Johnson's Tremfya (guselkumab), the National Medical Products Administration said in a notice on Friday.

J&J to buy remaining stake in Verb Surgical to strengthen digital surgery portfolio

Johnson & Johnson <JNJ.N> said on Friday it would acquire the remaining stake in Verb Surgical Inc, from Verily, Alphabet Inc's <GOOGL.O> life sciences division.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up